Robert A. Bradway, president and CEO at Amgen. Headquartered in Iceland, deCODE Genetics has discovered genetic risk factors for dozens of diseases, ranging from cardiovascular disease to cancer.

Amgen and UCB have suffered another setback as they try to build momentum for Evenity, their new antibody therapy for osteoporosis. The EMA’s Committee for Medicinal Products for Human Use (CHMP ...

At the heart of the dispute is whether Amgen's claims are ... court's view that companies that prove the commercial viability of products should not be penalized by small and inconclusive clinical ...

IMDYLLTRA offers new hope for patients with extensive-stage small cell lung cancer The UK’s Medicines and Healthcare products Regulatory Agency (MHRA ... Executive Medical Director, Amgen UK & Ireland ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. Read More on AMGN: Amgen NewsMORE Related Stocks Indices Commodities ...

Tapotoclax is under clinical development by Amgen and currently in Phase I for Relapsed Acute Myeloid Leukemia.